XSTO
FLUI
Market cap4mUSD
Oct 09, Last price
28.70SEK
1D
-1.37%
1Q
-20.28%
IPO
57.40%
Name
Fluicell AB
Chart & performance
P/E
—
P/S
6.57
EPS
—
Div yield, %
—
Shrs. gr., 5y
24.55%
Rev. gr., 5y
5.31%
Revenues
6m
+222.86%
Net income
-8m
L-46.28%
CFO
-5m
L-68.44%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Fluicell AB (publ) is a global provider of cutting-edge single-cell discovery platforms, catering to applications in biomedicine, drug development, and bioprinting. The company's product line includes the BioPen PRIME and BioPen FLEX microfluidic systems, engineered for precise localized solution delivery during single-cell experiments and for managing the chemical microenvironment of individual intact cells within tissue or cell cultures. Furthermore, Fluicell offers the Dynaflow Resolve system, a specialized platform for secondary ion channel screening that enables the measurement of various ion channel currents in a patch-clamp recording configuration. This Swedish company, headquartered in Gothenburg, was founded in 2012.
Key people
Victoire Viannay
Chief Executive Officer · since 2017
Mats Jonasson
Chief Financial Officer · since 2016
Gavin D.M. Jeffries
Chief Technology Officer, Director · since 2017
Owe Orwar
Director · since 2015
Daniel T. Chiu
Independent Director · since 2017
Carl Fhager
Independent Director · since 2017
Headquarters & legal address
Flöjelbergsgatan 8c
Mölndal, O 431 37
SE
Mölndal, O 431 37
SE
Address
Flojelbergsgatan 8c
Molndal, O 431 37
SE
Molndal, O 431 37
SE
Previous name
Aktiebolaget Grogrunden nr 2968
Previous name
Avalance Biotech AB
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||